DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment

Information source: Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cutaneous T Cell Lymphoma; Graft Versus Host Disease

Phase: N/A

Status: Recruiting

Sponsored by: Dartmouth-Hitchcock Medical Center

Official(s) and/or principal investigator(s):
Frederick Lansigan, MD, Principal Investigator, Affiliation: Dartmouth-Hitchcock Medical Center

Overall contact:
Frederick Lansigan, MD, Phone: 800-639-6918, Email: Cancer.Research.Nurse@Dartmouth.edu

Summary

Extracorporeal Photopheresis (ECP) is a form of apheresis and photodynamic therapy in which the peripheral blood is treated with 8-methoxypsoralen, which is then activated with UV light. ECP is currently a standard therapy for cutaneous T-cell lymphoma (CTCL) and is also effective for graft-versus-host disease (GVHD). The investigators would like to study the outcomes (response rates) of patients receiving ECP treatment and other factors relating to their disease and treatment, as well as procedural events, such as complications.

Clinical Details

Official title: Outcomes of Cutaneous T-Cell Lymphoma and Chronic Graft-Versus-Host Disease in Patients Treated With Extracorporeal Photopheresis

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: Response rates

Secondary outcome: Complications

Detailed description: The investigators intend to report outcomes from the inception of this procedure at Dartmouth-Hitchcock Medical Center (DHMC) in May 2008 through 9/30/11. Additionally, the investigators would like to maintain a prospective database of these patients so that new patient data can be collected for updating of outcomes.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients who receive Extracorporeal Photopheresis treatment

- Treated at Dartmouth-Hitchcock Medical Center

- Must be 18 years or older

Locations and Contacts

Frederick Lansigan, MD, Phone: 800-639-6918, Email: Cancer.Research.Nurse@Dartmouth.edu

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756, United States; Recruiting
Frederick Lansigan, MD, Phone: 800-639-6918, Email: Cancer.Research.Nurse@Dartmouth.edu
Frederick Lansigan, MD, Principal Investigator
Additional Information

Starting date: October 2011
Last updated: May 8, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017